Literature DB >> 8779847

Impact of extracellular buffer composition on cardioprotective efficacy of Na+/H+ exchanger inhibitors.

Y Shimada1, D J Hearse, M Avkiran.   

Abstract

There is controversy over whether the cardioprotective effects of Na+/H+ exchanger inhibitors are exerted primarily during ischemia or during subsequent reperfusion, possibly because of interstudy differences in experimental conditions. We studied the impact of perfusate buffer composition on the relative degree of protection afforded by Na+/H+ exchanger inhibition during ischemia vs. reperfusion. Isolated rat hearts (n = 8/group) were perfused (37 degrees C, 75 mmHg) with bicarbonate- or N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid-buffered medium and subjected to 20 min of global zero-flow ischemia and 45 min of reperfusion. One of two structurally distinct Na+/H+ exchanger inhibitors [5-(N,N-dimethyl)amiloride (DMA) or (3-methylsulfonyl-4-piperidinobenzoyl)guanidine methanesulfonate (HOE-694), 10 mumol/l] was transiently (5 min) infused 1) immediately before ischemia, 2) during initial reperfusion, or 3) during both of these periods. With bicarbonate-buffered medium, neither drug improved the postischemic recovery of left ventricular developed pressure (LVDP) when given only during reperfusion. In contrast, HOE-694 improved the postischemic recovery of LVDP from 39 +/- 5% in control to 66 +/- 6% (P < 0.05) when given before ischemia and from 33 +/- 4% in control to 65 +/- 4% (P < 0.05) when given before ischemia plus during reperfusion. With the latter protocol, the cardioprotective effect of HOE-694 occurred in a dose-dependent manner at 0.1-10 mumol/l. In contrast to the results with bicarbonate-buffered medium, in the presence of N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid-buffered medium, DMA and HOE-694 significantly improved recovery of LVDP (from 34 +/- 5% in controls to 56 +/- 3 and 71 +/- 8%, both P < 0.05) when given only during reperfusion. They also provided significant protection when given before ischemia or before ischemia plus during reperfusion; with the latter protocol, HOE-694 produced an almost complete recovery of LVDP (88 +/- 9 vs. 30 +/- 7% in controls, P < 0.05). In conclusion, our results suggest that the influence of Na+/H+ exchanger activity during reperfusion on the extent of functional recovery is modulated significantly by perfusate buffer composition. As a consequence, the cardioprotective efficacy of Na+/H+ exchanger inhibitors may be overestimated under bicarbonate-free conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8779847     DOI: 10.1152/ajpheart.1996.270.2.H692

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  5 in total

Review 1.  Regulation of cardiac sarcolemmal Na+/H+ exchanger activity: potential pathophysiological significance of endogenous mediators and oxidant stress.

Authors:  M Avkiran; A K Snabaitis
Journal:  J Thromb Thrombolysis       Date:  1999-07       Impact factor: 2.300

2.  Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53.

Authors:  K A Webster; D J Discher; S Kaiser; O Hernandez; B Sato; N H Bishopric
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

3.  Na(+)-H+ exchange inhibition at reperfusion is cardioprotective during myocardial ischemia-reperfusion; 31P NMR studies.

Authors:  J C Docherty; L Yang; G N Pierce; R Deslauriers
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

4.  Is the use of catecholamine before ischemic arrest safe? Effect of catecholamine on rat heart ischemia/reperfusion injury.

Authors:  Y Shimada; F Yamamoto; H Yamamoto; R Newling
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-07

5.  The role of Na+/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db/db mice.

Authors:  Ryuko Anzawa; Shingo Seki; Tomohisa Nagoshi; Ikuo Taniguchi; Danielle Feuvray; Michihiro Yoshimura
Journal:  Cardiovasc Diabetol       Date:  2012-04-11       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.